Bufothionine inhibits colorectal cancer progression via the STAT3/p53/SLC7A11 signaling axis
Frontiers in Pharmacology · 30.07.2026 · 17
DOI: 10.3389/fphar.2026.1885072 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 30.07.2026. Verfasst von Ruifang Xie und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Bufothionine, a major bioactive component of dried toad skin, has shown anti-tumor potential. However, its efficacy and underlying mechanisms in colorectal cancer (CRC) remain unclear.
Objective
This study aimed to investigate the therapeutic potential of bufothionine and its underlying mechanisms against CRC.
Methods
Anti-tumor efficacy was assessed using in vitro (CCK-8, migration assays) and in vivo (HT-29 xenograft) models. Network pharmacology, molecular docking and molecular dynamics simulations were employed to predict targets. Mechanisms were validated by biochemical assays, Western blot, IHC, and qPCR, with ferrostatin-1 applied to confirm ferroptosis specificity.
Results
Bufothionine significantly inhibited HT-29 cell proliferation and migration. Integrated network pharmacology and computational modeling identified p53 and STAT3 as core targets, with potential interactions predicted between bufothionine and key ferroptosis regulators (including SLC7A11). In vitro , bufothionine induced ferroptosis, characterized by increased Fe 2+ , ROS, and MDA levels, and a decreased GSH/GSSG ratio; these effects were partially reversed by ferrostatin-1. In vivo , bufothionine reduced tumor weight indices, improved liver function by attenuating AST and ALP elevations without hepatosplenic toxicity, and regulated inflammatory cytokines. Mechanistically, bufothionine suppressed inflammatory activation (NLRP3, IL-1β), inhibited STAT3 phosphorylation, and modulated p53 activity, leading to the subsequent inhibition of the SLC7A11/GPX4 axis in both cells and tumor tissues.
Conclusion
Bufothionine suppresses CRC by the STAT3/p53/SLC7A11 signaling axis in a manner associated with ferroptosis, suggesting its potential as a therapeutic agent for colorectal cancer.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Zitieren
APA
Xie, R., Xiang, N., Zhou, G., Tan, Z., Feng, Y., Chen, L., & Zhou, X. (2026). Bufothionine inhibits colorectal cancer progression via the STAT3/p53/SLC7A11 signaling axis. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1885072
Vancouver
Xie R, Xiang N, Zhou G, Tan Z, Feng Y, Chen L, et al. Bufothionine inhibits colorectal cancer progression via the STAT3/p53/SLC7A11 signaling axis. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1885072
BibTeX
@article{Xie2026,
author = {Xie, Ruifang and Xiang, Nan and Zhou, Gui and Tan, Zeye and Feng, Yiming and Chen, Lingru and Zhou, Xin},
title = {Bufothionine inhibits colorectal cancer progression via the STAT3/p53/SLC7A11 signaling axis},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1885072}
}
EUVIMED